April 21, 2024

Medical Trend

Medical News and Medical Resources

Russia-Ukraine conflict may limit the supply of Russia’s Sputnik V vaccine

Russia-Ukraine conflict may limit the supply of Russia’s Sputnik V vaccine


Russia-Ukraine conflict may limit the supply of Russia’s Sputnik V vaccine.

Russia has been seeking approval from the World Health Organization (WHO) for its Sputnik V vaccine for some time , but the program may not be approved due to the Russian-Ukrainian conflict.


Sputnik V is the world’s first approved vaccine against the new coronavirus, showing efficacy against a variety of new coronavirus variants, but has not been recognized by Western countries including the European Union and the United States so far.


Russia-Ukraine conflict may limit the supply of Russia's Sputnik V vaccine


The Russian Direct Investment Fund (RDIF) has been struggling to seek approval from the WHO and the European Medicines Agency (EMA) , but concerns over data and production issues at the latter have slowed the process.


Russian commerce has been strained by international pressure as U.S.-led economic sanctions against Russia have tightened. The RDIF issued a statement saying it was not politically active and claimed that sanctions prohibiting the expanded use of “Sputnik V” showed that the U.S. government “chosen the path of undermining constructive dialogue among nations.” The RDIF said the measures announced by the United States to restrict its movement were political choices that went against the principles of humanitarian cooperation.


“Restrictions imposed by U.S. authorities complicate RDIF’s efforts to promote Russian vaccine products internationally, which some large Western pharmaceutical companies have lobbied for.

As a result of this unfair competition, billions of people around the world may not have access to effective vaccines. and safe Russian-made vaccines,” RDIF said in an emailed statement to BioSpace.


Earlier this month, a WHO official revealed to Russia’s Tass news agency that the global health organization plans to visit a vaccine production facility in Russia. It is unclear whether the visit took place before Russia’s attack on Ukraine.


Russia has been pushing for approval mandates in multiple markets around the world.

A few days ago, the Republic of Kazakhstan authorized the use of the Russian vaccine for adolescents aged 12-17.

The RDIF said it was the first country outside Russia to grant such authorization to paediatric patients.


Now because of the war, the promotion of the vaccine has been hindered by some.

This week, the German state government of Bavaria announced that the Sputnik V vaccine would not be used in the Free State of Bavaria, even if the EMA approves its use in member states.

A year ago, the Bavarian government signed a letter of intent with RDIF to secure 2.5 million doses of the Russian vaccine after EMA approval.


“From our point of view, it is incredible that this project is now possible,” Markus Soeder, the governor of Germany’s southeastern state, said in a Reuters report . Soeder said the reason was the Russian attack on Ukraine.

Reuters noted that Russian pharmaceutical company R-Pharm had set up a production facility in Bavaria ahead of EMA approval to build regional production capacity in Germany, which was also in talks with the Russian government over a vaccine.

As Western economic sanctions against Russia grow, it is unclear whether this will limit Russia’s ability to ship vaccines to areas with weak production capacity.

The Sputnik V vaccine is an adenovirus-vectored vaccine developed by the Gamaleya Institute in Moscow. The vaccine is genetically designed to infect cells so that they make the spike protein of the new coronavirus, which causes infection with the new coronavirus.

The data showed that the vaccine produced a strong and durable immune response against the new coronavirus, including the Omicron variant .

According to the Russian side, in a comparative study conducted in Italy, it was found that the Sputnik V vaccine was more than 2 times higher than the two doses of Pfizer’s mRNA vaccine against the virus-neutralizing antibody of the Omicron variant.

The RDIF noted that the Sputnik V vaccine has been licensed in 71 countries, covering more than 4 billion people.


Although the vaccine has shown efficacy against the virus, several countries, including the United States and Ukraine, have claimed that foreigners who have been vaccinated against Sputnik V will not be allowed entry unless they test negative for the new coronavirus.

Both the Ukrainian and U.S. governments require WHO-approved vaccines. In a report last fall, Reuters noted that the Ukrainian government had refused to buy the Sputnik V vaccine and had sought international assistance to ensure access to vaccines produced elsewhere.




Russia-Ukraine conflict may limit the supply of Russia’s Sputnik V vaccine

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.